Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: Results from two Phase 3 studies
Journal Reference: RMD Open 2024;10:e004202 doi: 10.1136/rmdopen-2024-004202
Bimekizumab (BKZ) treatment led to early improvements in physical function, sleep, work productivity, and overall health-related quality of life at Week 16 in patients across the full axSpA disease spectrum, which were sustained through Week 52. Dubreuil et al. investigated treatment impact over one year using BASFI, MOS-Sleep-R, SF-36 PCS/MCS, WPAI:axSpA, and ASQoL scores in patients with both non-radiographic and radiographic axSpA.
Higher proportions of BKZ-randomised patients achieved more stringent Week 16 thresholds for improvement compared with PBO in BASFI, SF-36 PCS, and ASQoL. Week 52 responses were comparable regardless of whether originally randomised to BKZ or PBO.
Keywords:
